2022-000747-77: A Study to Assess if BIIB122 Tablets are Safe and can Slow Worsening of Early-Stage Parkinson's Disease in Participants with Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale |
|
|
| Not yet recruiting | 3 | 400 | Europe | BIIB122, DNL151, Tablet | Biogen Idec Research Limited, BIOGEN IDEC RESEARCH LIMITED, Biogen Idec Research Limited | Parkinson's Disease, Parkinson's Disease, Diseases [C] - Nervous System Diseases [C10] | | | | |
LIGHTHOUSE, NCT05418673: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale |
|
|
| Terminated | 3 | 7 | Europe, US | BIIB122, DNL151, BIIB122-Matching Placebo | Biogen, Denali Therapeutics Inc. | Parkinson Disease | 07/23 | 07/23 | | |
